Skip to main content
NIH funding notice PA-15-106

Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R21)

Closed on January 7, 2018.

Posted
January 29, 2015
Close date
January 7, 2018
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $225,055 in first-year total cost, median $225,055.

Most frequent study sections

  1. AIDS Molecular and Cellular Biology Study Section[AMCB]1

Most frequent institutions

  1. BETH ISRAEL DEACONESS MEDICAL CENTER1
Competing awards under PA-15-106 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2016Measurement of Antibody Epitope Signatures by Peptide Microarrays to Determine Recency of HIV Infection1R21AI122938-01HENRICH, TIMOTHY JENSENSTEPHENSON, KATHRYN ELAINEBETH ISRAEL DEACONESS MEDICAL CENTER, MA$225,055AMCB

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PA-15-106: Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R21) | ScienceDex | ConductScience